GlassScriptPhysician profile
Gregorio S Pineda
NPI 1184603151
$4,483.41
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,310 · 2020: $1,108 · 2021: $65.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $512.23 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $478.06 | 2019-2020 | |
| Emd Serono, INC. | $426.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $353.70 | 2019-2020 | |
| Abbott Laboratories | $228.64 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $165.23 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $159.35 | 2019 | |
| Biogen, INC. | $152.33 | 2019-2020 | |
| Neurelis, INC. | $151.89 | 2020-2021 | |
| Ucb, INC. | $151.13 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $138.63 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $134.72 | 2019-2020 | |
| Mdd US Operations, LLC | $130.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $129.28 | 2019-2020 | |
| Akcea Therapeutics, INC. | $121.15 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $110.72 | 2019-2020 | |
| Allergan, INC. | $110.36 | 2019 | |
| Greenwich Biosciences, INC. | $93.59 | 2019 | |
| Merz North America, INC. | $86.77 | 2019 | |
| Genzyme Corporation | $85.15 | 2019 | |
| Eisai INC. | $81.69 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $81.67 | 2019 | |
| Sk Life Science, INC. | $78.27 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $77.63 | 2019-2020 | |
| Sarepta Therapeutics, INC. | $44.88 | 2019 | |
| Saol Therapeutics INC. | $35.98 | 2019 | |
| Lilly USA, LLC | $24.43 | 2019 | |
| Amgen INC. | $24.31 | 2019 | |
| Abbvie INC. | $20.98 | 2021 | |
| Boston Scientific Corporation | $20.76 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.10 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.54 | 2020 | |
| Mallinckrodt Enterprises LLC | $16.63 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregorio Pineda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.